Skip to main content

Unable to load price data. Sorry.


Nymox Pharmaceutical Corp (NASDAQOTCBB:NYMX.F)

CAPS Rating: No stars

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

64 Outperform
53 Underperform

All-Star Players

8 Outperform
21 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQOTCBB:NYMX.F Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

OklaBoston (34.36)
Submitted January 05, 2020

Improving technicals as much as anything else.

mjonesy1985 (92.76)
Submitted April 13, 2015

good entry point will be .99 - $1.01

Fools bullish on NASDAQOTCBB:NYMX.F are also bullish on:

Fools bearish on NASDAQOTCBB:NYMX.F are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NYMX.F.


Member Avatar OklaBoston (34.36) Submitted: 1/5/2020 5:03:31 PM : Outperform Start Price: $2.51 NASDAQ OTC:NYMX.F Score: -104.99

Improving technicals as much as anything else.


Member Avatar Bigsef77 (48.90) Submitted: 10/3/2018 1:22:56 PM : Outperform Start Price: $1.47 NASDAQ OTC:NYMX.F Score: -152.11

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
GlobeNewswire•October 3, 2018

HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.

FT is Nymox's lead drug for which the Company is in the process of seeking U.S. and European marketing approvals for BPH (prostate enlargement), and FT is also in late stage development for prostate cancer. Pivotal trial results for FT BPH studies involving 977 treated patients were published in 2018 in the prestigious World Journal of Urology (May 2018, Volume 36, pages 801–809), and the safety and efficacy results have been presented to the American Urology Association and previously to the European Association of Urology.

Dr. Paul Averback, CEO of Nymox said, "For prostate cancer in particular, repeated injection treatments will be needed and a focal molecular treatment will have negligible value if there cannot be reliable safety expected from repeated injection. Prostate cancer is a multi-focal disease and it is to be expected that multiple focal molecular treatments will be utilized for optimal outcomes. Follow-up and re-treatment will be needed. Nymox undertook 2 large FT re-injection safety studies in 2010-2014 involving 351 subjects with BPH, who were subsequently followed for up to 7 years. These mandatory and adequately sized safety studies are absolutely required in order to demonstrate safety of re-injection, and this is a standard requirement."

Dr Averback added, "In addition, Nymox undertook extensive immunological testing involving over 1000 subject samples, demonstrating that FT does not lead to detectable antibody formation, which underlines FT safety and supports the lack of risk for allergic reactions. All laboratory testing and sexual function tests including semen analyses showed no changes in FT treated men compared to controls."

Nymox's lead drug Fexapotide (FT) has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 977 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo group study an 82-95% reduction in the number of these patients who required surgery after they received FT in the trial, as compared to patients who did not receive FT but instead later received conventional approved BPH treatments (p<.0001).


Member Avatar superstar2 (96.03) Submitted: 9/13/2016 12:15:20 PM : Outperform Start Price: $3.69 NASDAQ OTC:NYMX.F Score: -187.81

Impressive stage3 trial results on lead drug Fexapotide.


Find the members with the highest scoring picks in NYMX.F.

Score Leader


BetapegAnalytics (< 20) Score: +443.22

The Score Leader is the player with the highest score across all their picks in NYMX.F.

Member Name Member
Call Time
Score Commentary
BetapegAnalytics < 20 8/18/2009 Underperform 5Y $4.51 -79.48% +363.74% +443.22 0 Comment
BicaChica 97.58 10/12/2009 Underperform 5Y $4.66 -80.14% +322.01% +402.15 0 Comment
roth450 < 20 7/23/2010 Underperform NS $3.80 -75.64% +316.29% +391.94 0 Comment
longtermgrowth09 60.31 12/17/2009 Underperform 5Y $4.27 -78.33% +310.73% +389.06 0 Comment
RUMBLINstrflame 93.39 12/2/2009 Underperform 5Y $4.52 -79.52% +308.66% +388.19 0 Comment
Okcfirefighter < 20 12/17/2010 Underperform 5Y $7.20 -87.15% +265.74% +352.89 0 Comment
boardwalken65 29.36 7/5/2011 Underperform 3M $8.24 -88.77% +239.93% +328.70 0 Comment
NetscribeHealthC 71.55 3/23/2007 Underperform 1Y $5.95 -84.45% +235.55% +320.00 1 Comment
Theory1 < 20 6/3/2008 Underperform NS $3.93 -76.45% +242.14% +318.59 0 Comment
flyboyl6 29.53 2/6/2007 Underperform NS $5.42 -82.92% +233.62% +316.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NYMX.F.